Publication date: Jun 27, 2025
One of the main challenges in cancer medicine today is to find ways to predict which patients will benefit from these therapies before treatment begins. Would you briefly explain how mitochondrial DNA differs from chromosomal DNA?TK: Immune checkpoint blockade has changed the way we treat several cancers, including advanced melanoma. Recognizing these differences could help us develop better, more personalized treatment plans. MedicalResearch. com: Does the MT haplogroup T (HG-T) predict complete resistance to checkpoint therapy or earlier relapse? This approach is key to personalizing care and improving outcomes. RF: Mitochondria are small structures inside our cells that produce the energy needed for cells to function. (In other words, would some patient still want to try immunotherapy in hopes of a brief remission from their metastatic melanoma, even if they carry the mutation? Scientists can categorize this mitochondrial DNA into groups called haplogroups, based on unique variations in the genetic code. Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma.
| Concepts | Keywords |
|---|---|
| Benz | Based |
| Cancer | Checkpoint |
| June | Com |
| Party | Haplogroup |
| Phdsenior | Hg |
| Immune | |
| Immunotherapy | |
| Krm | |
| Medicalresearch | |
| Melanoma | |
| Mitochondrial | |
| Nyu | |
| Rf | |
| Treatment |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | relapse |
| drug | DRUGBANK | Tropicamide |
| pathway | REACTOME | Immune System |
| drug | DRUGBANK | Nivolumab |
| drug | DRUGBANK | Nonoxynol-9 |
| disease | MESH | Cancer |
| drug | DRUGBANK | Coenzyme M |
| pathway | KEGG | Melanoma |
| disease | MESH | Melanoma |